Telaprevir to boceprevir switch highlights lack of cross-reactivity.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23166191.
- Also identified by DOI 10.1093/cid/cis960 and PMC identifier 3732052.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hepatitis C viral protease inhibitors increase sustained virologic response rates compared to interferon and ribavirin but also add side effects. Telaprevir and boceprevir are structurally similar, and share cross-resistant mutations. This case report highlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir.
Medical subject headings
- Antiviral Agents
- Eosinophilia
- Exanthema
- Hepatitis C, Chronic
- Oligopeptides
- Proline